Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F23%3A00577739" target="_blank" >RIV/86652036:_____/23:00577739 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/062791260/publication/US11773182B2?q=US11773182" target="_blank" >https://worldwide.espacenet.com/patent/search/family/062791260/publication/US11773182B2?q=US11773182</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
Original language description
The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US11773182
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Oct 3, 2023
Owner name
The Johns Hopkins University, Biotechnologický ústav AV ČR, v. v. i
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence